drugset / Trial / NCT07353957
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Timeline
- Start
- 2025-03-27
- Primary completion
- 2028-05-31
- Completion
- 2031-02-27
Outcome
Outcome not reported
Stopped (Business): “This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Petosemtamab | Monoclonal antibody | — | — |